On May 17, 2024, aesco solutions, a leading group for production and development services (CDMO) for medical device companies, and D11Z. Ventures GmbH & Co. KG (formerly Zukunftsfonds Heilbronn) announce the closing of the acquisition of seleon GmbH.

Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner.

How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.

App for tuberculosis diagnosis - 15/05/2024

"Find-TB" aims to improve access to tuberculosis diagnostics

Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.

Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.

Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI?

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

Press release - 24/04/2024

Strengthening the healthcare sector in the state: BIOPRO Baden-Württemberg networks itself strategically at a European level

BIOPRO has been supporting Baden-Württemberg as a healthcare location for many years and provides important incentives for its further development.  The state company has been a member of the Council of European Bioregions (CEBR) network since April 2024. Within the CEBR, BIOPRO aims to network with European cooperation partners in order to provide even better support for the innovative capacity of the healthcare industry in Baden-Württemberg.

PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.

Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.

Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail.

Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.

With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.

Epifadin from the nasal microbiome - 28/03/2024

From the nose: novel antibiotic substance discovered

Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.

Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).